Get the Stockscreener App
6.255
0.97%
0.065
Candel Therapeutics Inc stock is traded at $6.255, with a volume of 57,594.
It is up +0.97% in the last 24 hours and up +30.48% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$6.19
Open:
$6.28
24h Volume:
57,594
Relative Volume:
0.07
Market Cap:
$342.55M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-3.7012
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
+14.26%
1M Performance:
+30.48%
6M Performance:
+25.75%
1Y Performance:
+3.82%
1-Day Range:
$6.16
$6.32
1-Week Range:
$5.405
$6.64
52-Week Range:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.24 | 339.80M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.19 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.29 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.50 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.59 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Will Candel Therapeutics Inc. stock deliver strong dividend growth2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
What MACD signals say about Candel Therapeutics Inc.Market Risk Report & Real-Time Volume Analysis - newser.com
Analyzing drawdowns of Candel Therapeutics Inc. with statistical tools2025 Price Momentum & Scalable Portfolio Growth Ideas - newser.com
How to interpret RSI for Candel Therapeutics Inc. stockWeekly Loss Report & Daily Momentum Trading Reports - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Is Candel Therapeutics Inc a good long term investmentProtective Put Strategies & Outstanding Wealth Building - earlytimes.in
Visual trend scoring systems applied to Candel Therapeutics Inc.July 2025 Price Swings & High Win Rate Trade Tips - newser.com
Price momentum metrics for Candel Therapeutics Inc. explainedWeekly Trading Summary & Community Verified Trade Signals - newser.com
Candel Therapeutics stock rating reiterated at Buy by H.C. Wainwright - Investing.com
How resilient is Candel Therapeutics Inc. stock in market downturns2025 Market Overview & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Candel Therapeutics Inc. stock bottoming outQuarterly Trade Summary & Community Consensus Trade Signals - newser.com
Why Candel Therapeutics Inc. stock remains undervalued2025 Earnings Surprises & Reliable Entry Point Trade Alerts - newser.com
Candel Therapeutics to present insights from enLIGHTEN Discovery Platform at SITC 2025 meeting - Proactive financial news
Candel Therapeutics to Present at the SITC 2025 Annual Meeting - The Manila Times
Candel Therapeutics to Present New Insights on Immunotherapy at SITC 40th Annual Meeting - Quiver Quantitative
Positive Phase 3 CAN-2409 data — Candel Therapeutics presents prostate cancer & NSCLC at SITC Nov 2025 - Stock Titan
Is Candel Therapeutics Inc. stock a smart buy before Fed meetingMarket Growth Summary & Stock Portfolio Risk Control - newser.com
Using Ichimoku Cloud for Candel Therapeutics Inc. technicals2025 Buyback Activity & Precise Buy Zone Tips - newser.com
Candel Therapeutics’ CAN-2409 delivers durable benefit in positive phase 3 prostate cancer trial - Proactive financial news
Tanager Wealth Management LLP Purchases New Shares in Candel Therapeutics, Inc. $CADL - MarketBeat
H.C. Wainwright reiterates Buy rating on Candel Therapeutics stock at $23 price target - Investing.com Australia
Candel Therapeutics Inc. stock retracement – recovery analysisLayoff News & Daily Growth Stock Investment Tips - newser.com
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - 富途牛牛
HC Wainwright & Co. Reiterates Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating | CADL Stock News - GuruFocus
CADL Analyst Rating: HC Wainwright & Co. Maintains 'Buy' Rating - GuruFocus
HC Wainwright Reiterates "Buy" Rating for Candel Therapeutics (NASDAQ:CADL) - MarketBeat
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025 - GlobeNewswire
Candel Therapeutics presents phase 3 clinical trial of CAN-2409 - MarketScreener
Candel trial shows promise for gene therapy in prostate cancer - Proactive financial news
Candel Therapeutics Reports Positive Phase 3 Trial Results for CAN-2409 in Intermediate-to-High-Risk Localized Prostate Cancer at ASTRO 2025 - Quiver Quantitative
30% Better Survival: Candel's Breakthrough Prostate Cancer Drug Shows Success Across All Radiation Types - Stock Titan
What analysts say about Candel Therapeutics Inc stockPrice Action Trading & Reap the Rewards of Patience + Planning - Early Times
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
2.36%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):